Home › NCT07573163

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

A Randomized Clinical Trial of Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults aged 18 years and older
* Diagnosis of MACS, defined as morning cortisol \>1.8 mcg/dL after a 1 mg dexamethasone suppression test
* Elevated blood pressure (SBP ≥120 mmHg or DBP ≥80 mmHg per the 2025 American College of Cardiology/American Heart Association \[ACC/AHA\] criteria, or current use of antihypertensive medication)
* BMI ≥27
* Undergoing or having undergone adrenalectomy for the treatment of MACS

Exclusion Criteria:

* Bilateral adrenal lesions
* Adrenal malignancy
* Concurrent primary aldosteronism with MACS
* Current use of GLP-1 receptor agonists
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
* Pregnancy or breastfeeding

About the study

Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery.

This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.

What is being tested

• Tirzepatide (drug)
• Standard medical treatment (other)

Sponsor: Alaa Sada · Participants: 34 · Started: Jul 27, 2026

Contact the study team

• Meghan Kelley · Phone: 4125789429

Official record on ClinicalTrials.gov — NCT07573163

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.